Enhertu is a cancer drug brand (trastuzumab deruxtecan) developed by AstraZeneca and Daiichi Sankyo, approved for HER2-positive cancers; the treatment has spurred ongoing debate and regulatory attention as evidence of efficacy and safety evolves.